Astrazeneca ADR Stock
Price
Target price
€73.50
€73.50
0.680%
0.5
0.680%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Astrazeneca ADR Stock
Astrazeneca ADR gained 0.680% compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | 0.680% | 2.817% | 0.000% | 22.689% | 14.063% | 18.893% | 55.983% |
| GSK plc ADR | 0.000% | 0.493% | 9.677% | 21.429% | 24.390% | 22.892% | 4.615% |
| Bayer AG ADR | 0.790% | -3.053% | -9.286% | 4.959% | 28.024% | -52.612% | -40.094% |
| Novo Nordisk A/S ADR | -2.110% | -7.143% | -20.980% | -58.961% | -51.794% | -64.336% | -32.269% |
News
Why AstraZeneca Stock Topped the Market on Thursday
Veteran pharmaceutical company AstraZeneca (NASDAQ: AZN) delivered for investors on the second-to-last trading day of the week. Its shares rose by more than 3% across that trading session, thanks
Fortune 500 Leaders Share AI-powered Supply Chain Excellence on Stage at OMP Conference
Industry giants, including AstraZeneca, Johnson & Johnson, General Mills, and Kraft Heinz, to present real-world case studies in Miami
MIAMI, FL / ACCESS Newswire / October 22, 2025 / OMP,
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Investing in pharmaceutical stocks can carry risks. It's not always clear which drugs will be successful and turn into blockbusters for their respective businesses. As a result, it can take years